<DOC>
	<DOC>NCT00665093</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.</brief_summary>
	<brief_title>Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Levemir® above 6 yrs NovoMix® 30 above 18 yrs Patients with Type 1 or Type 2 diabetes, including newly diagnosed Current treatment with NovoMix® 30 or Levemir®</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>